Shionogi Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SHIONOGI INC, and what generic alternatives to SHIONOGI INC drugs are available?
SHIONOGI INC has five approved drugs.
There are four US patents protecting SHIONOGI INC drugs.
There are seventy-two patent family members on SHIONOGI INC drugs in thirty-eight countries and thirty-three supplementary protection certificates in sixteen countries.
Drugs and US Patents for Shionogi Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shionogi Inc | COGNEX | tacrine hydrochloride | CAPSULE;ORAL | 020070-003 | Sep 9, 1993 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Shionogi Inc | ULESFIA | benzyl alcohol | LOTION;TOPICAL | 022129-001 | Apr 9, 2009 | DISCN | Yes | No | 7,294,342 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Shionogi Inc | COGNEX | tacrine hydrochloride | CAPSULE;ORAL | 020070-002 | Sep 9, 1993 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Shionogi Inc | FETROJA | cefiderocol sulfate tosylate | POWDER;INTRAVENOUS | 209445-001 | Nov 14, 2019 | RX | Yes | Yes | 9,238,657 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Shionogi Inc | FETROJA | cefiderocol sulfate tosylate | POWDER;INTRAVENOUS | 209445-001 | Nov 14, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Shionogi Inc | COGNEX | tacrine hydrochloride | CAPSULE;ORAL | 020070-004 | Sep 9, 1993 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Shionogi Inc | RYBIX ODT | tramadol hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 021693-001 | May 5, 2005 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Shionogi Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Shionogi Inc | COGNEX | tacrine hydrochloride | CAPSULE;ORAL | 020070-004 | Sep 9, 1993 | 4,631,286 | ⤷ Try a Trial |
Shionogi Inc | COGNEX | tacrine hydrochloride | CAPSULE;ORAL | 020070-002 | Sep 9, 1993 | 4,631,286 | ⤷ Try a Trial |
Shionogi Inc | COGNEX | tacrine hydrochloride | CAPSULE;ORAL | 020070-001 | Sep 9, 1993 | 4,631,286 | ⤷ Try a Trial |
Shionogi Inc | DORIBAX | doripenem | INJECTABLE;INTRAVENOUS | 022106-002 | Oct 5, 2010 | 8,247,402 | ⤷ Try a Trial |
Shionogi Inc | DORIBAX | doripenem | INJECTABLE;INTRAVENOUS | 022106-001 | Oct 12, 2007 | 8,247,402 | ⤷ Try a Trial |
Shionogi Inc | ULESFIA | benzyl alcohol | LOTION;TOPICAL | 022129-001 | Apr 9, 2009 | 5,858,383 | ⤷ Try a Trial |
Shionogi Inc | COGNEX | tacrine hydrochloride | CAPSULE;ORAL | 020070-003 | Sep 9, 1993 | 4,816,456 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for SHIONOGI INC drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Injection | 250 mg/vial and 500 mg/vial | ➤ Subscribe | 2011-10-11 |
➤ Subscribe | Lotion | 5% | ➤ Subscribe | 2016-04-11 |
International Patents for Shionogi Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Colombia | 6331443 | ⤷ Try a Trial |
Serbia | 62449 | ⤷ Try a Trial |
Chile | 2011000939 | ⤷ Try a Trial |
Brazil | 112017004166 | ⤷ Try a Trial |
Hungary | S2000042 | ⤷ Try a Trial |
Australia | 2009310959 | ⤷ Try a Trial |
Slovenia | 3190115 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Shionogi Inc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2960244 | CR 2020 00049 | Denmark | ⤷ Try a Trial | PRODUCT NAME: CEFIDEROCOL, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT; REG. NO/DATE: EU/1/20/1434 20200424 |
0528678 | 09C0005 | France | ⤷ Try a Trial | PRODUCT NAME: DORIPENEME; REGISTRATION NO/DATE IN FRANCE: EU/1/07/467/001 DU 20080725; REGISTRATION NO/DATE AT EEC: EU/1/08/467/001 DU 20080725 |
2960244 | SPC/GB20/053 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: CEFIDEROCOL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE; REGISTERED: UK EU/1/20/1434 (NI) 20200424; UK PLGB 50999/0009 20200424 |
0528678 | 2009/002 | Ireland | ⤷ Try a Trial | PRODUCT NAME: DORIPENEM.; REGISTRATION NO/DATE: EU/1/08/467/001 20080725 |
2960244 | C20200033 00355 | Estonia | ⤷ Try a Trial | PRODUCT NAME: TSEFIDEROKOOL;REG NO/DATE: EU/1/20/1434 24.04.2020 |
0658161 | SPC/GB01/003 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: N-(4-(2(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE MALEIC ACID, "ROSIGLITAZONE MALEATE", ITS TAUTOMERS AND PHARMACEUTICALLY ACCEPTABLE SOLVATES; REGISTERED: CH 55176 02 19990929; CH 55176 03 19990929; CH 55176 04 19990929; UK EU/1/00/137/001 20000711; UK EU/1/00/137/002 20000711; UK EU/1/00/137/003 20000711; UK EU/1/00/137/004 20000711; UK EU/1/00/137/005 20000711; UK EU/1/00/137/006 20000711; UK EU/1/00/137/007 20000711; UK EU/1/00/137/008 20000711; UK EU/1/00/137/009 20000711; UK EU/1/00/137/010 20000711; UK EU/1/00/137/011 20000711; UK EU/1/00/137/012 20000711 |
2960244 | 2020/044 | Ireland | ⤷ Try a Trial | PRODUCT NAME: CEFIDEROCOL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE; NAT REGISTRATION NO/DATE: EU/1/20/1434 20200424; FIRST REGISTRATION NO/DATE: EU/1/20/1434 20200424 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.